Long-term oral antibiotic treatment: why, what, when and to whom?

Eva Van Braeckel, Menno M. van der Eerden

Source: Eur Respir Monogr 2017; 75: 185-205
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstractFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Eva Van Braeckel, Menno M. van der Eerden. Long-term oral antibiotic treatment: why, what, when and to whom?. Eur Respir Monogr 2017; 75: 185-205

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
TB vaccination: why, when, how and what?
Source: International Congress 2014 – PG20 Global evaluation of tuberculosis from children to adults
Year: 2014

Positional therapy: who, when and how?
Source: Sleep and Breathing Conference 2021
Year: 2021

Eradication and long-term antibiotic treatment: does it make sense?
Source: International Congress 2014 – PG08 The management of non-CF bronchiectasis: from childhood to adulthood
Year: 2014

TB following targeted and biological therapy: can we predict it?
Source: Virtual Congress 2020 – Tuberculosis and comorbidities
Year: 2020

What do new data concerning triple therapy tell us about the risk of infection?
Source: International Congress 2019 – Exploring the link between inhaled corticosteroids and respiratory infection
Year: 2019

Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think?
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018

Pharmacotherapy of CSA: who, when and how?
Source: Sleep and Breathing Conference 2021
Year: 2021

Immunotherapy: when, who and which drug?
Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer
Year: 2018

What’s new in induction therapy
Source: ERS Course 2016
Year: 2016

Cleaning agents and asthma: what does the evidence currently tell us about diagnosis and management of these cases?
Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health?
Year: 2018

Antifungals in pulmonary infections: to whom, when and how?
Source: Eur Respir Monogr 2017; 75: 159-184
Year: 2017

How often do asthma patients claim prescribed therapy?
Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS
Year: 2017

Optimising bronchodilator therapy in COPD: Who, why and when?
Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care
Year: 2019

What happens when an oral tuberculosis is not treated?
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007

Macrolide therapy in asthma: limited treatment, long-term improvement
Source: Eur Respir J 2009; 33: 1239
Year: 2009

Evaluating disease-modifying treatment in CF: are we ready to take the challenge?
Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases"
Year: 2014